Bryan, Garnier & Co announces the IPO of Quantum Pharma on London AIM

Share the transaction

Paris and London, January 12th, 2015 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful Initial Public Offering of Quantum Pharma on AIM, a market operated by the London Stock Exchange plc, with a global offering of £106m. Bryan, Garnier & Co acted alongside Zeus Capital.

Quantum Pharma successfully raised £106.1 million by placing 106.1 million vendor and new ordinary shares with investors at a placing price of 100 pence per ordinary share. Quantum’s market capitalisation on admission, based on the placing price, is approximately £125 million. Quantum Pharma started trading on December 11th, 2014 and the company’s ticker is ‘QP.’.

The net proceeds of the placing will be used by Quantum Pharma to repay a proportion of the debt within the business, enable it to acquire the remaining shares in Colonis Pharma Limited, the specialist pharmaceutical product development business, that it does not already own, and help accelerate the execution of the Group’s strategy.

Quantum Pharma Plc is a growing manufacturer, supplier and service provider to pharmaceutical wholesalers, retail pharmacy, hospitals, pharmaceutical companies, homecare and care home markets. Specials and Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from wholesale pharmacy suppliers. Quantum has a product range of over 22,000 Special and Special Obtain products. It regularly services around 6,500 pharmacies and over 240 hospital accounts across the UK.

Olivier Garnier, Managing Partner, said: “Quantum Pharma exemplifies the fast-growing healthcare companies Bryan Garnier & Co aims to accompany in their various corporate finance needs. This successful transaction confirms our expertise in healthcare as well as our pan-European reach. Bryan Garnier completed 11 significant ECM transactions for more than €500m in 2014, a vast majority of which in healthcare.”

For more information, please contact

Olivier Garnier – Managing Partner

ogarnier@bryangarnier.com | +33 1 56 68 75 29

Hervé Ronin – Managing Director, Healthcare

hronin@bryangarnier.com | +33 1 70 35 57 22

About Quantum Pharma 

Quantum Pharma is a growing manufacturer, supplier and service provider to the wholesale and retail pharmacy, hospital, homecare and care-home markets. Based in a purpose-built facility in Burnopfield, County Durham, the Group manufactures and sources non-standard pharmaceutical products. Formed in 2004, Quantum has grown significantly in recent years (both organically and by acquisition) and now employs over 320 people.

The Group operates through five business units: Quantum Pharmaceutical, a supplier of Specials and Special Obtains, U L Medicines, a supplier of unlicensed imports, Colonis, a specialist pharmaceutical product development business, Biodose, a patent-protected medicine delivery system, and Quantum Aseptics, a supplier of intravenous dosage form aseptic products.

(www.quantumpharmaplc.com)

Privacy Preference Center